These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22211928)

  • 1. Conversion to tacrolimus once-daily from ciclosporin in stable kidney transplant recipients: a multicenter study.
    Rostaing L; Sánchez-Fructuoso A; Franco A; Glyda M; Kuypers DR; Jaray J
    Transpl Int; 2012 Apr; 25(4):391-400. PubMed ID: 22211928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing ciclosporin-related side-effects.
    Margreiter R; Pohanka E; Sparacino V; Sperschneider H; Kunzendorf U; Huber W; Lameire N; Andreucci VE; Donati D; Heemann U;
    Transpl Int; 2005 Jul; 18(7):816-23. PubMed ID: 15948861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients.
    Pohanka E; Margreiter R; Sparacino V; Sperschneider H;
    Transplant Proc; 2005 May; 37(4):1874-6. PubMed ID: 15919490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of cardiovascular risk factors and cosmetic side effects in kidney transplant recipients after conversion to tacrolimus.
    Zadrazil J; Horak P; Zahalkova J; Strebl P; Horcicka V; Krejci K; Bachleda P; Dedochova J; Valkovsky I
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):67-73. PubMed ID: 19365530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis.
    Busque S; Demers P; St-Louis G; Boily JG; Tousignant J; Lemieux F; Smeesters C; Corman J; Daloze P
    Transplant Proc; 1998 Jun; 30(4):1247-8. PubMed ID: 9636507
    [No Abstract]   [Full Text] [Related]  

  • 6. [Hypertrichosis and gingival hypertrophy regression in renal transplants following the substitution of cyclosporin by tacrolimus].
    Busque S; Demers P; Saint-Louis G; Boily JG; Tousignant J; Lemieux F; Martin G; Smeesters C; Corman J; Daloze P
    Ann Chir; 1999; 53(8):687-9. PubMed ID: 10584376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid-free immunosuppression in kidney transplant recipients and prograf monotherapy: an interim analysis of a prospective multicenter trial.
    Bäckman L; Aselius H; Lindberger K; Svensson L; Strömbom U; Olausson E; Hadimeri H; Deurell SI; Norrby J; Gäbel M; Ebermark A; Olausson M
    Transplant Proc; 2006 Oct; 38(8):2654-6. PubMed ID: 17098029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy.
    Tang SC; Chan KW; Tang CS; Lam MF; Leung CY; Tse KC; Li CS; Ho YW; Tong MK; Lai KN; Chan TM;
    Nephrol Dial Transplant; 2006 Nov; 21(11):3243-51. PubMed ID: 16877482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy.
    Videla CO
    Transplant Proc; 2009; 41(6):2659-63. PubMed ID: 19715995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal function and safety in stable kidney transplant recipients converted from immediate-release to prolonged-release tacrolimus.
    Lauzurica R; Morales JM; van Hooff J;
    Transpl Int; 2012 Jan; 25(1):48-55. PubMed ID: 21992068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients.
    Beckebaum S; Klein C; Varghese J; Sotiropoulos GC; Saner F; Schmitz K; Gerken G; Paul A; Cicinnati VR
    Aliment Pharmacol Ther; 2009 Oct; 30(8):834-42. PubMed ID: 19624550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight.
    Neal DA; Gimson AE; Gibbs P; Alexander GJ
    Liver Transpl; 2001 Jun; 7(6):533-9. PubMed ID: 11443583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol.
    Thorp M; DeMattos A; Bennett W; Barry J; Norman D
    Transplantation; 2000 Mar; 69(6):1218-20. PubMed ID: 10762229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion.
    White M; Haddad H; Leblanc MH; Giannetti N; Pflugfelder P; Davies R; Isaac D; Burton J; Chan M; Azevedo E; Howlett J; Ignaszewski A; Busque S; Cantarovich M; Ferguson R; Genest J; Ross H
    J Heart Lung Transplant; 2005 Jul; 24(7):798-809. PubMed ID: 15982605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved kidney graft function after conversion from twice daily tacrolimus to a once daily prolonged-release formulation.
    Kolonko A; Chudek J; Wiecek A
    Transplant Proc; 2011 Oct; 43(8):2950-3. PubMed ID: 21996198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors.
    Meçule A; Poli L; Nofroni I; Bachetoni A; Tinti F; Umbro I; Barile M; Berloco PB; Mitterhofer AP
    Transplant Proc; 2010 May; 42(4):1317-9. PubMed ID: 20534290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations.
    Alloway R; Vanhaecke J; Yonan N; White M; Haddad H; Rábago G; Tymchak W; Diaz Molina B; Grimm M; Eiskjaer H; Karpf C; Undre N
    J Heart Lung Transplant; 2011 Sep; 30(9):1003-10. PubMed ID: 21493098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study.
    Marcén R; Chahin J; Alarcón A; Bravo J
    Transplant Proc; 2006 Oct; 38(8):2427-30. PubMed ID: 17097957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.